Table 1

Cohort description

CharacteristicACF cohortAPC trial overall
Placebo twice daily (n = 17)200 mg celecoxib twice daily (n = 15)400 mg celecoxib twice daily (n = 13)Placebo twice daily (n = 679)200 mg celecoxib twice daily (n= 685)400 mg celecoxib twice daily (n = 671)
Age (y), median (range)61 (51-81)59 (38-70)63 (50-78)59 (31-88)59 (35-83)59 (34-87)
Male sex, n (%)17 (100.0)13 (86.7)12 (92.3)473 (69.7)460 (67.2)454 (67.7)
Body mass index in males, mean ± SE28.5 ± 1.130.0 ± 1.731.6 ± 1.928.8 ± 0.228.9 ± 0.228.6 ± 0.2
Current cigarette smoker, n (%)1 (5.9)5 (33.3)1 (7.7)122 (18.0)119 (17.4)96 (14.3)
Colorectal cancer in a parent, n (%)5 (29.4)5 (33.3)2 (15.4)140 (20.6)147 (21.5)142 (21.2)
No. adenomas at baseline, median ± SE2.0 ± 1.22.0 ± 1.52.0 ± 1.92.0 ± 0.12.1 ± 0.12.1 ± 0.1
At least one adenoma ≥1 cm, n (%)8 (47.0)5 (33.3)4 (30.8)288 (42.4)303 (44.2)291 (43.4)
Advanced adenoma* at baseline, n (%)9 (52.9%)5 (33.3)4 (30.8)341 (50.2)354 (51.7)333 (49.6)
Hyperplastic polyp detected during a study colonoscopy, n (%)6 (35.3)6 (40.0)6 (46.2)268 (39.5)271 (39.6)276 (41.1)
  • *Features of an advanced adenoma are size ≥1.0 cm, villous or tubulovillous histology, high-grade dysplasia, and/or invasive cancer.